Andere Sprachen Relmada Therapeutics, Inc. OTC Markets

Aktien

A2PSZF

US75955J4022

RLMD

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:34:09 17.07.2024			% 5 Tage	% 1. Jan.
3.665 ^USD	0.00%		+8.91%	+139.13%

12.06.	Transcript : Relmada Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 11:20 AM
05.06.	RELMADA THERAPEUTICS, INC. : Goldman Sachs gibt eine Verkaufsbewertung ab	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Revolutionizes Drug Testing Ensuring Workplace Safety; Poised for Global Expansion	11.07.
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell Microcap Growth Index	01.07.
Relmada Therapeutics, Inc.(NasdaqGS:RLMD) added to Russell 3000E Growth Index	01.07.
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry	18.06.
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	10.06.
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference	03.06.
Relmada Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	08.05.
Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Relmada Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024	06.05.
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results	20.03.
Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024	12.03.
Relmada Therapeutics to Participate in the Leerink Partners Global Biopharma Conference	05.03.
Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor	04.01.
Relmada Therapeutics Provides Corporate Update	04.01.
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer	03.01.
Relmada Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.
Relmada Therapeutics to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on November 8, 2023	03.11.
Relmada Therapeutics Reports Positive Preclinical Data on its Psilocybin Program to Treat Liver Disease	11.10.23
Relmada Therapeutics to Present New Preclinical Data on Its Psilocybin Program At AASLD the Liver Meeting 2023	11.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Relmada Therapeutics, Inc. OTC Markets

Aktien

A2PSZF

US75955J4022

RLMD

Andere Sprachen

Filter